These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Infectious disease. Elusive pathogen cornered at last. Youngsteadt E Science; 2008 Mar; 319(5871):1747. PubMed ID: 18369112 [No Abstract] [Full Text] [Related]
16. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). Kibadi K; Boelaert M; Fraga AG; Kayinua M; Longatto-Filho A; Minuku JB; Mputu-Yamba JB; Muyembe-Tamfum JJ; Pedrosa J; Roux JJ; Meyers WM; Portaels F PLoS Negl Trop Dis; 2010 Jul; 4(7):e736. PubMed ID: 20625556 [TBL] [Abstract][Full Text] [Related]
17. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473 [TBL] [Abstract][Full Text] [Related]
18. Buruli ulcer caused by "Mycobacterium ulcerans subsp. shinshuense". Watanabe T; Ohkusu K; Nakanaga K; Ishii N; Nakashima K; Shindo M; Yoshida Y; Yamamoto O Eur J Dermatol; 2010; 20(6):809-10. PubMed ID: 20822972 [No Abstract] [Full Text] [Related]
19. Compliance with antimicrobial therapy for buruli ulcer. Klis S; Kingma R; Tuah W; Stienstra Y; van der Werf TS Antimicrob Agents Chemother; 2014 Oct; 58(10):6340. PubMed ID: 25225342 [No Abstract] [Full Text] [Related]
20. Reply to "compliance with antimicrobial therapy for buruli ulcer". Phillips RO; Sarfo FS; Abass MK; Frimpong M; Ampadu E; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M Antimicrob Agents Chemother; 2014 Oct; 58(10):6341. PubMed ID: 25225343 [No Abstract] [Full Text] [Related] [Next] [New Search]